Results 71 to 80 of about 1,361 (136)

Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers. [PDF]

Ther Adv Med Oncol
Lebeau A, Kakkos A, Leroi N, Bours V, Delbecque K, Goffin F, Gonne E, Gennigens C.   +7 more
europepmc   +1 more source

Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. [PDF]

Int J Mol Sci
Zhang Z, Harish R, Elahi N, Saini S, Telia A, Kundlas M, Koroleva A, Umoh IN, Lota M, Bilkhu M, Kawaiah A, Allala MR, Leukeu A, Nebuwa E, Sharifi N, Ashton AW, Jiao X, Pestell RG.   +17 more
europepmc   +1 more source

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma. [PDF]

J Exp Clin Cancer Res
Farrell A, Dall G, Vandenberg CJ, Shield-Artin K, Kyran EL, Blackmore T, Lim R, Taylor R, Neagle C, Ratnayake G, Tan T, Mouradov D, Hadla A, Jarman K, Beard S, Jarratt A, Penington JS, Wakefield MJ, Papenfuss AT, Scott CL, Barker HE.   +20 more
europepmc   +1 more source

Fundamentals and emerging frontiers in p53-targeted drug development. [PDF]

Biochem Biophys Rep
Long HD, Zhang N, Wang WE, Ma YS, Liu FX, Chen ZY, Lu CN, Wang XF, Han N, Cai YF, Yang C, Tang XM, Yu H, Jiang H, Fu D, Chu KJ, Wu WG.   +16 more
europepmc   +1 more source

Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma. [PDF]

Cells
Gramantieri L, Vianello C, Leoni I, Galvani G, Monti E, Bella M, Marisi G, Salamon I, Ferracin M, Ravegnini G, Giovannini C, Stefanelli C, Lazzari ML, Piscaglia F, Coada CA, Bassi C, Negrini M, Casadei-Gardini A, Foschi GF, Trerè D, Fornari F.   +20 more
europepmc   +1 more source

Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. [PDF]

BMC Cancer
Ziener J, Henao-Restrepo JA, Leonhardi J, Sturm MJ, Becker S, Morales-Prieto DM, Milde T, Beck JF, Sonnemann J.   +8 more
europepmc   +1 more source

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor. [PDF]

Discov Oncol
Honda N, Taniguchi H, Ono S, Hayashi F, Imamura E, Gyotoku H, Takemoto S, Takazono T, Ishimoto H, Sakamoto N, Obase Y, Masutani M, Nishino T, Mukae H.   +13 more
europepmc   +1 more source

Current progress in targeting mitotic kinases in PDAC. [PDF]

RSC Med Chem
Barlow TMA, Rooman I, Ballet S.
europepmc   +1 more source

Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C. [PDF]

Br J Cancer
van Megesen K, Stefan A, Kieboom M, Amico R, Jansen AML, Borel Rinkes I, Kranenburg O.   +6 more
europepmc   +1 more source

Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition. [PDF]

Oncogene
Xi Q, Kunita A, Ogawa M, Ka M, Tanimoto S, Tsuchimochi S, Nagai S, Matsunaga A, Fukuda T, Watanabe K, Sone K, Shinozaki-Ushiku A, Kawana K, Ushiku T, Osuga Y, Katayama K, Kage H, Oda K.   +17 more
europepmc   +1 more source